Chris Wigley
Chris Wigley is CEO at Genomics England since October 2019, and currently interim SRO for Data at NHSX supporting the tech response to COVID-19.
Genomics England Ltd (GEL) is a government-owned company, at the intersection of research and clinical genomics. Our mission is to bring the benefits of Genomic Medicine to everyone. GEL was set up in 2014 to complete the 100,000 Genomes Project, which brought many thousands of new diagnoses to sick patients and generated a globally unique data source for research. In early 2020 we will, in partnership with the NHS, be translating the learnings from the â100kâ into a clinical whole genome service targeting the diagnosis and treatment of rare diseases and cancer, while exploring the potential of pharmacogenomics and pilots for newborn screening.
Genomics England Ltd (GEL) is a government-owned company, at the intersection of research and clinical genomics. Our mission is to bring the benefits of Genomic Medicine to everyone. GEL was set up in 2014 to complete the 100,000 Genomes Project, which brought many thousands of new diagnoses to sick patients and generated a globally unique data source for research. In early 2020 we will, in partnership with the NHS, be translating the learnings from the â100kâ into a clinical whole genome service targeting the diagnosis and treatment of rare diseases and cancer, while exploring the potential of pharmacogenomics and pilots for newborn screening.